title: NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats.
abstract: BACKGROUND
  Recent experiments from this laboratory demonstrated synergistic effects of AMPA/kainate receptor blockade and D(2/3) dopamine (DA) receptor stimulation on brain stimulation reward and locomotor activity.
  
  
  OBJECTIVE
  Using place conditioning, this study explored further the interaction between DA and glutamate (Glu) using the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801, the AMPA/kainate receptor antagonist NBQX, and the D(2/3) DA receptor agonist 7-OH-DPAT.
  
  
  METHODS
  Effects of these compounds, alone and combined, were measured in male Sprague--Dawley rats using an unbiased two-compartment place conditioning procedure.
  
  
  RESULTS
  7-OH-DPAT (0.03--5.0 mg kg(-1), s.c.) administered immediately prior to conditioning was ineffective; when administered 15 min prior to conditioning, only the highest dose (5.0 mg kg(-1), s.c.) induced conditioned place preference (CPP). Acquisition of 7-OH-DPAT-induced CPP was blocked by MK-801 (0.06 or 0.13 mg kg(-1), i.p.) or NBQX (0.5 microg) microinjected into the nucleus accumbens (NAS) shell subregion. Intra-NAS shell administration of 7-OH-DPAT (5.0 microg) or NBQX (0.5 microg), alone or combined, failed to induce place conditioning, and this lack of effect was not due to state dependency. Administration of MK-801 or 7-OH-DPAT (5.0 mg kg(-1)) during the conditioning phase acutely increased horizontal activity, but neither compound, alone or combined, induced conditioned locomotor effects.
  
  
  CONCLUSIONS
  Acquisition of place conditioning induced by systemic administration of 7-OH-DPAT is blocked by systemic NMDA receptor antagonism by MK-801 or by the AMPA/kainate receptor antagonist NBQX microinjected into the NAS shell subregion.
authors.affiliation: Department of Sociology, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Anna-Maria
authors.initials: AM
authors.lastname: Biondo
authors.forename: Robert L H
authors.initials: RL
authors.lastname: Clements
authors.forename: David J
authors.initials: DJ
authors.lastname: Hayes
authors.forename: Brendan
authors.initials: B
authors.lastname: Eshpeter
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Greenshaw
mesh_terms: D000818:Animals; D002755:Choice Behavior; D003213:Conditioning, Psychological / Q000187:drug effects*; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D050637:Receptors, Dopamine D3; D018092:Kainic Acid Receptors / Q000037:antagonists & inhibitors*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology
chemical_list: D016291:Dizocilpine Maleate; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018091:Receptors, AMPA; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D018092:Kainic Acid Receptors; D016194:Receptors, N-Methyl-D-Aspartate; D013764:Tetrahydronaphthalenes; C493595:Drd3 protein, rat; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; C031349:7-hydroxy-2-N,N-dipropylaminotetralin
references.citation: J Neural Transm Gen Sect. 1994;95(1):71-4
references.pmid: 7857588
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):315-22
references.pmid: 2968613
references.citation: Brain Res. 1995 Oct 30;697 (1-2):76-82
references.pmid: 8593597
references.citation: Behav Pharmacol. 1998 Sep;9(5-6):457-67
references.pmid: 9832931
references.citation: J Pharmacol Exp Ther. 1992 Feb;260(2):742-7
references.pmid: 1371159
references.citation: Psychopharmacology (Berl). 1996 Dec;128(4):413-20
references.pmid: 8986012
references.citation: Pharmacol Biochem Behav. 1996 Oct;55(2):209-14
references.pmid: 8951956
references.citation: Eur J Pharmacol. 1995 Feb 14;274(1-3):47-55
references.pmid: 7768280
references.citation: J Neural Transm Gen Sect. 1995;101(1-3):27-39
references.pmid: 8695055
references.citation: Brain Res. 1993 Aug 27;620(2):339-42
references.pmid: 8369967
references.citation: J Neurosurg. 1950 May;7(3):256-60
references.pmid: 15415783
references.citation: Pharmacol Biochem Behav. 2000 Nov;67(3):637-45
references.pmid: 11164096
references.citation: Behav Brain Res. 1989 Sep 1;34(3):239-46
references.pmid: 2551338
references.citation: Psychopharmacology (Berl). 1992;107(4):591-4
references.pmid: 1534911
references.citation: Eur J Pharmacol. 1996 Dec 30;318(2-3):251-6
references.pmid: 9016912
references.citation: Eur J Pharmacol. 1998 Dec 4;362(2-3):103-10
references.pmid: 9874159
references.citation: Psychopharmacology (Berl). 1997 Dec;134(3):266-76
references.pmid: 9438676
references.citation: Brain Res Bull. 1997;44(3):221-7
references.pmid: 9323434
references.citation: J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66
references.pmid: 8531103
references.citation: Eur J Pharmacol. 1993 Nov 16;249(3):R9-10
references.pmid: 8287911
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1997 Jul;21(5):839-52
references.pmid: 9278955
references.citation: Neurosci Res. 1995 Jul;22(4):427-30
references.pmid: 7478308
references.citation: Neurosci Lett. 1995 Jun 23;193(1):37-40
references.pmid: 7566661
references.citation: Neuroreport. 2003 Jan 20;14 (1):93-8
references.pmid: 12544838
references.citation: J Neurosci Methods. 1997 Dec 30;78(1-2):169-72
references.pmid: 9497013
references.citation: Psychopharmacology (Berl). 2000 May;150(1):102-11
references.pmid: 10867982
references.citation: J Neural Transm Gen Sect. 1995;101(1-3):115-26
references.pmid: 8695042
references.citation: Behav Brain Res. 2005 Mar 7;158(1):79-88
references.pmid: 15680196
references.citation: Pol J Pharmacol. 1994 Jan-Apr;46(1-2):79-81
references.pmid: 7981776
references.citation: J Pharmacol Exp Ther. 2003 Sep;306(3):1068-76
references.pmid: 12805481
references.citation: Pharmacol Biochem Behav. 1999 Aug;63(4):569-80
references.pmid: 10462185
references.citation: J Neurosci. 1998 Sep 15;18(18):7502-10
references.pmid: 9736668
references.citation: Pain. 1994 Sep;58(3):355-66
references.pmid: 7838585
references.citation: Behav Brain Res. 1997 Mar;84(1-2):99-107
references.pmid: 9079776
references.citation: Alcohol Alcohol. 1999 Mar-Apr;34(2):175-82
references.pmid: 10344778
references.citation: Behav Pharmacol. 1992 Aug;3(4):415-421
references.pmid: 11224144
references.citation: Psychopharmacology (Berl). 1999 Mar;143(1):39-46
references.pmid: 10227078
references.citation: Nature. 1990 Sep 13;347(6289):146-51
references.pmid: 1975644
references.citation: Brain Res. 1995 Mar 6;673(2):242-50
references.pmid: 7606438
references.citation: Psychopharmacology (Berl). 1989;99(1):87-90
references.pmid: 2550989
references.citation: Pol J Pharmacol. 1996 Jul-Aug;48(4):425-30
references.pmid: 9112683
references.citation: Eur J Pharmacol. 1994 Aug 22;261(3):R5-6
references.pmid: 7813542
references.citation: Neuropharmacology. 1993 May;32(5):509-10
references.pmid: 8321432
references.citation: Behav Pharmacol. 1996 Aug;7(4):303-314
references.pmid: 11224423
references.citation: Neurosci Lett. 1998 Feb 13;242(2):114-6
references.pmid: 9533407
references.citation: Proc Natl Acad Sci U S A. 1986 Sep;83(18):7104-8
references.pmid: 3529096
references.citation: Eur J Neurosci. 1999 Nov;11(11):4089-98
references.pmid: 10583497
references.citation: Psychopharmacology (Berl). 1985;87(2):225-32
references.pmid: 3931151
references.citation: Life Sci. 2002 Apr 26;70(23):2799-810
references.pmid: 12269384
references.citation: Science. 1983 Jun 17;220(4603):1304-6
references.pmid: 6857251
references.citation: Behav Pharmacol. 1996 Jan;7(1):105-109
references.pmid: 11224401
references.citation: Pharmacol Biochem Behav. 1994 May;48(1):111-8
references.pmid: 8029281
references.citation: Physiol Behav. 1989 Oct;46(4):755-8
references.pmid: 2557649
references.citation: Brain Res. 1993 Jul 23;617(2):267-73
references.pmid: 8402155
references.citation: J Pharmacol Exp Ther. 1997 May;281(2):928-40
references.pmid: 9152403
references.citation: Behav Pharmacol. 1993;4(4):429-442
references.pmid: 11224212
references.citation: Brain Res. 1982 Dec 16;253(1-2):185-93
references.pmid: 6817850
references.citation: Behav Neural Biol. 1994 Jul;62(1):50-9
references.pmid: 7945145
references.citation: Life Sci. 1981 Nov 2;29(18):1881-6
references.pmid: 7311722
references.citation: Eur J Pharmacol. 1996 Dec 19;317(2-3):191-6
references.pmid: 8997600
references.citation: Neuropharmacology. 1997 Jul;36(7):961-71
references.pmid: 9257940
references.citation: Brain Res Bull. 1996;40(3):201-7
references.pmid: 8736582
references.citation: Pol J Pharmacol. 2000 May-Jun;52(3):179-85
references.pmid: 11055574
references.citation: Eur J Pharmacol. 1996 Jun 13;306(1-3):23-32
references.pmid: 8813611
references.citation: J Pharmacol Exp Ther. 1999 Jul;290(1):9-15
references.pmid: 10381753
references.citation: Pharmacol Biochem Behav. 1999 Nov;64(3):591-5
references.pmid: 10548276
references.citation: Brain Res. 1991 Oct 18;562(1):164-8
references.pmid: 1839240
references.citation: Psychopharmacology (Berl). 1995 Dec;122(4):351-7
references.pmid: 8657832
references.citation: Pharmacol Biochem Behav. 1993 Jan;44(1):245-7
references.pmid: 8430127
references.citation: Pharmacol Biochem Behav. 1994 Apr;47(4):907-12
references.pmid: 8029261
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 1;89(17 ):8155-9
references.pmid: 1518841
references.citation: Pharmacol Biochem Behav. 1999 Jan;62(1):159-64
references.pmid: 9972859
references.citation: Eur J Pharmacol. 1999 Dec 3;385(2-3):99-102
references.pmid: 10607864
references.citation: Eur J Pharmacol. 2001 Oct 5;428(2):203-14
references.pmid: 11675037
references.citation: J Comp Neurol. 1992 Jun 8;320(2):145-60
references.pmid: 1377716